TriMas Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRS research report →
Range $38 – $38
Price Chart
About the company
TriMas Corporation (TRS) is a global industrial company focused on the engineering, manufacturing, and distribution of a diverse range of products spanning consumer, aerospace, and industrial markets. Its operations are structured into three primary segments: Packaging, Aerospace, and Specialty Products. The Packaging division delivers numerous solutions for dispensing and sealing.
- CEO
- Thomas J. Snyder
- IPO
- 2007
- Employees
- 3,700
- HQ
- Bloomfield Hills, MI, US
Get TickerSpark's AI analysis on TRS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.30B
- P/E
- 1.55
- Fwd P/E
- 22.33
- PEG
- 0.00
- P/S
- 2.00
- P/B
- 0.93
- EV/EBITDA
- 5.92
- Div Yield
- 0.42%
- Gross Margin
- 20.69%
- Op Margin
- 4.19%
- Net Margin
- 135.18%
- ROE
- 72.53%
- ROIC
- 1.44%
Latest fiscal year · YoY change
- Revenue
- $645.72M+2.4%
- Gross Profit
- $131.24M+6.5%
- Op Income
- $14.05M
- Net Income
- $120.14M+395.4%
- EPS
- $2.97+395.0%
- OCF Growth
- +84.1%
- FCF Growth
- +439.0%
- 52W High
- $45.43
- 52W Low
- $31.67
- 50D MA
- $38.65
- 200D MA
- $38.91
- Beta
- 0.62
- RSI (14)
- 46
- Avg Volume
- 374.19K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
TriMas posted higher sales and sharply better earnings in Q3, lifted by cost actions and Packaging strength, while Specialty Products remained pressured by Norris Cylinder throughput issues.· October 29, 2026
- Q3 net sales rose 7.7% to $178.7 million, with organic growth of 7.2%.
- Adjusted EPS increased to $0.50 from $0.17 a year ago, and operating profit rose 47.9% to $13.6 million.
- Packaging continued to perform well, with sales up 8.8% to $148 million and operating margin up to 13.8%.
- Specialty Products remained constrained by machine downtime and productivity issues; operating profit fell to $0.1 million from $2.4 million.
- The company reaffirmed full-year adjusted EPS of $1.60-$1.70 and lifted its full-year sales outlook to 4%-6% growth for the combined businesses.
TriMas reported third-quarter 2026 net sales of $178.7 million, up 7.7% year over year, with organic growth of 7.2%. Operating profit increased 47.9% to $13.6 million and operating margin expanded 200 basis points to 7.6%; adjusted EPS was $0.50 versus $0.17 in the prior-year period. Year to date, net sales rose 6.4% to $521.6 million, operating profit increased 35.8% to $41.2 million, and EPS more than doubled to $1.25. Packaging Q3 sales were $148 million, up 8.8%, with operating profit of $20.4 million and margin of 13.8%; Specialty Products sales were about $31 million, up 2.7%, with operating profit of $0.1 million. For 2026, TriMas reaffirmed adjusted EPS guidance of $1.60-$1.70, expects combined Packaging and Specialty Products sales growth of 4%-6%, and still expects operating profit margin expansion of 250 basis points. Packaging full-year sales growth outlook is 4%-5% and full-year operating margin is expected to be nearly 14%; Specialty Products full-year sales growth is expected to be 7%-10% and operating margin 4%-6%.
Tom Snyder emphasized that 2026 is about strengthening execution, improving operations, and reshaping the portfolio for longer-term value creation. He said the company is making progress on cost reductions, leadership changes, and operational excellence, even if not all benefits are yet showing up in the numbers. He also highlighted the Rapak divestiture as a step toward a more focused portfolio and said TriMas will remain patient and disciplined with M&A and capital deployment.
Paul Swart focused on the financial flexibility created by the Aerospace divestiture, citing more than $1.1 billion in cash, a net cash position of about $761 million, and nearly $184 million spent on share repurchases through the end of Q3. He said third-quarter free cash flow was nearly $21 million versus $4 million a year ago, and that cash investments earned an average yield of about 3.9% during the quarter. He also noted the company has paid approximately two-thirds of the Aerospace-related tax obligation and expects to fund the rest over the next couple of quarters; the $400 million of 4 1/8% senior notes due 2029 leave no near-term debt maturities.
Analysts focused on the M&A pipeline, the Rapak divestiture, Packaging pricing/margin pressure, and the timing of a recovery at Norris Cylinder. Management said the M&A pipeline remains active but selective, with continued interest in life sciences and packaging opportunities, though there was nothing specific to announce. On Packaging, Paul said the weaker-than-expected price/cost benefit was mainly because resin costs did not fall as quickly as forecast, but he still expects recovery over time. On Norris, management said two key machines are now running near expected levels and expects Q4 margin improvement versus Q3, but cautioned that a full normalization will take time and likely extend beyond this year.
The company delivered a solid quarter with double-digit profit growth, and management said cost reduction actions and operational improvements are beginning to show up in results. Packaging appears healthy, the Rapak sale should improve the portfolio mix, and management said underlying demand at Norris remains strong with market share gains still intact. TriMas also has substantial cash and liquidity, giving it room to repurchase shares and pursue M&A selectively.
The main issue on the call was the continued operational disruption at Norris Cylinder, where downtime, labor inefficiencies, and throughput constraints compressed margins. Packaging also saw some margin pressure from a less favorable mix and resin costs that did not decline as quickly as expected. Management also acknowledged that not all of the expected operational improvement will be immediate, and that recovery in Specialty Products will take more time.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 74.2%
- Shares Outstanding
- 35.87M
- Float Shares
- 26.61M
of shares held by institutions
213 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for TRS, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Michael T. McCaulHouse · TX10 | Sell | Mar 4, 25 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Nov 7, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Aug 28, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Nov 1, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Nov 1, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Dec 14, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | May 5, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | May 5, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Feb 15, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Feb 15, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jan 28, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jan 28, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Dec 14, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 3.58M | ▲ 8.87K |
| Blackrock, Inc. | 3.04M | ▲ 509.66K |
| Dimensional Fund Advisors LP | 2.28M | ▲ 16.20K |
| American Century Companies Inc | 1.86M | ▲ 712.30K |
| Vanguard Portfolio Management LLC | 1.75M | ▲ 73.26K |
| Vanguard Capital Management LLC | 1.42M | ▲ 10.63K |
| Allspring Global Investments Holdings, LLC | 1.42M | ▼ 484.91K |
| Advisory Research Inc | 1.17M | ▼ 37.45K |
| Permian Investment Partners, LP | 1.17M | ▼ 37.09K |
| Geode Capital Management, LLC | 955.91K | ▼ 63.37K |
| Punch & Associates Investment Management, Inc. | 807.29K | ▲ 562.57K |
| State Street Corp | 745.96K | ▼ 38.18K |
Held by 318 ETFs
Biggest fund positions in TRS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Tredwell Daniel P | buy | 66.975 |
| Oct 13, 26 | SEDAGHAT SHAWN | other | 651 |
| Aug 12, 26 | Tredwell Daniel P | buy | 63.692 |
| Jul 14, 26 | SEDAGHAT SHAWN | other | 615 |
| Jun 30, 26 | Parker Herbert K | sell | 15,000 |
| Jun 24, 26 | Snyder Thomas James | other | 22,155 |
| May 13, 26 | Tredwell Daniel P | buy | 62.142 |
| May 5, 26 | Robin Jodi F. | sell | 3,000 |
| May 7, 26 | Robin Jodi F. | sell | 2,000 |
| Apr 14, 26 | SEDAGHAT SHAWN | other | 640 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TRS coverage
Recent articles, reports, and earnings notes.
No research on TRS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRS report →SSR Mining: Marigold TRS And Roxmore Acquisition Highlight Multi-Decade Americas Pivot
seekingalpha.com · Nov 9
All You Need to Know About TriMas (TRS) Rating Upgrade to Buy
zacks.com · Nov 4
Do Options Traders Know Something About TriMas Stock We Don't?
zacks.com · Nov 4
WOODWARD PARK PARTNERS ADVISES TRIMAS IN ITS SALE OF RAPAK TO RINGMETALL
prnewswire.com · Nov 2
What TriMas (TRS) Said on Its Q3 Earnings Call
marketbeat.com · Oct 29
TriMas Corporation (TRS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
TriMas (TRS) Q3 Earnings Match Estimates
zacks.com · Oct 29
TriMas Reports Third Quarter 2026 Results
businesswire.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.